Suchergebnisse - "Fu, Chengcheng"

PubPharm (4)

1

Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma : Updated Analysis of LEPUS

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Fu, W. | Li, W. | Hu, J. | +17

2

Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma : a phase 1, dose-escalation study (MMY1003)

enthalten in: Annals of hematology | 2022

von Jing, H. | Yang, L. | Qi, J. | +10

3

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma : Phase 3 LEPUS (MMY3009) Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2021

von Lu, J. | Fu, W. | Li, W. | +17

4

Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial : a multi-center study

enthalten in: Annals of hematology | 2020

von Li, J. | Bao, L. | Xia, Z. | +17

1
[1]